Pro 2014-017 (Jianfeng Group Disposal of Assets Announcement)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2014-017
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Disposal of Assets by Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
l Brief Content: The Jiangnan Pharmaceutical Factory of Zhejiang Jianfeng Pharmaceutical Co., Ltd., a controlling subsidiary of the Company, located at 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, is to be demolished. Recently, the Jinhua Economic and Technological Development Zone Management Committee and Zhejiang Jianfeng Pharmaceutical Co., Ltd. signed an Agreement to expropriate the land and other assets of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory, and compensate for the expropriated land and real estate. The total compensation is 95.9167 million yuan (RMB).
l This matter does not constitute a related party transaction
l This matter does not constitute a major asset reorganization
l There are no major legal obstacles to the implementation of this matter
l According to the provisions of the Company's Articles of Association, this matter needs to be submitted to the Board of Directors of the Company for consideration, but does not need to the shareholders' meeting for consideration.
1. Overview
(I) In view of the fact that Jinhua municipal government has carried out renovation and demolition of enterprises in Jinhua Jiangnan Development Zone in order to speed up economic transformation and urban transformation. The company's holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical") is located at No. 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, and the Jiangnan Pharmaceutical Factory is planned to be demolished. June 2014 30 , Jinhua Economic and Technological Development Zone Management Committee (hereinafter referred to as "Jinhua Economic Management Committee") and Zhejiang Jianfeng Pharmaceutical Co., Ltd. signed the Agreement. Jinhua Economic Management Committee will purchase and store 37016.3 ㎡ of land from Jiangnan Pharmaceutical Factory of Jianfeng Pharmaceutical Co., Ltd. and compensate and reward the expropriated land, real estate and other assets. The total amount of compensation and reward is 95.9167 million yuan (RMB).
(II) Board of Directors Review
The company held the 17th meeting of the 8th board of directors by correspondence on June 30, 2014. All eight directors of the company participated in the voting, the board of directors passed the "Proposal on Demolition of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory" with 8 votes in favor, 0 votes against and 0 abstentions.
(III) According to the Articles of Association of the Company, the disposal of the asset is not required to be submitted to the General Meeting of Shareholders for consideration.
2. The main bodies of both parties
The main bodies of both parties in this asset disposal are the Management Committee of Jinhua Economic and Technological Development Zone and Zhejiang Jianfeng Pharmaceutical Co., Ltd., a holding subsidiary of the Company.
3. Disposal of Assets
(I) Basic Information
Involving this demolition is the overall assets such as houses, equipment and land use rights of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory. The property rights of this part of the assets are clear, there are no mortgages, pledges or any other restrictions on transfer, no judicial matters such as seizure, freezing, litigation or arbitration, and no other circumstances that hinder the transfer of assets.
Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory is the main production base of Jianfeng Pharmaceutical's solid preparations. It was transformed on the basis of the acquisition of Jinhua Monosodium glutamate Factory in 1994. There are existing production lines and supporting facilities for tablets, dripping pills, freeze-dried powder injections, cephalosporin aseptic sub-packaging powder injections, bulk drugs, etc. Among them, the production lines for tablets and dripping pills are in normal production, freeze-dried powder injection, cephalosporin aseptic powder injection, raw materials and other production lines in Jinxi base for off-site transformation.
(II) Asset Evaluation
. For this asset transfer, Kunyuan Asset Evaluation Co., Ltd., which is qualified to engage in securities and futures business, was hired to conduct asset evaluation and issued "Asset Evaluation Report " (Kunyuan Evaluation Report [2014] No. 221). The base date of the assessment is April 30, 2014. For assets such as houses, pipelines and non-removable equipment, the replacement cost method is mainly used to determine their assessed value ; for non-removable trees, according to their specific varieties, specifications and other major parameters, the current market price is used as the compensation value; for removable equipment, according to the current relevant market price standards, the compensation value is based on the reasonable relocation expenses required for its protective demolition in the original factory area and its relocation to the new factory area to resume normal use. As for the land use right, Jinhua Huacheng Real Estate Land Evaluation Co., Ltd. entrusted Jinhua Huacheng Real Estate Land Evaluation Co., Ltd. to evaluate the land use right and issued "Land Evaluation Report ". This appraisal is based on the value of the land use rights contained in the appraisal report as its demolition compensation value. The evaluation results are listed below:
Project |
Net Book Value (Yuan) |
Appraisal Value (Yuan) |
Value Added (Yuan) |
Value Added Ratio (yuan) |
1. Housing Compensation Value |
10455370.00 |
21273590.00 |
10818220.00 |
103.47% |
2. Structures compensation Value |
2741175.40 |
3907960.00 |
1166784.60 |
42.57% |
3. Pipeline and Other Concealed Works Compensation Value |
1016483.53 |
847130.00 |
-169353.53 |
-16.66 |
4. Seedling Greening Compensation Value |
1354860.00 |
1354860.00 |
||
5. non-removable equipment compensation value |
3632714.15 |
3862560.00 |
229845.85 |
6.33% |
6. Removable Equipment Compensation Value |
1936160.00 |
|||
7. Land Compensation Value |
4678895.40 |
37756626.00 |
33077730.60 |
706.96% |
Total |
22524638.48 |
70938886.00 |
46478087.52 |
206.34% |
this evaluation, the value-added of the house appraisal was 103.47 per cent and the value-added of the land appraisal was 706.96 per cent, mainly due to the fact that the land of the plant was acquired earlier and the cost of building the house was lower. In addition, the assessed value of the compensation value of the removable equipment is based on the reasonable relocation costs required for the protective demolition of the part of the equipment and the relocation to the new plant area to return to normal use, not the replacement value of the part of the equipment.
2. This asset transfer is based on the "Asset Appraisal Report" issued by Kunyuan Asset Appraisal Co., Ltd., and the compensation and incentives for the demolished assets are determined through negotiation between the two parties. The main contents of the
4. agreement
"Jinhua Economic Management Committee" or "Party A": Jinhua Economic and Technological Development Zone Management Committee
"Jianfeng Pharmaceutical" or "Party B": Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Party A and Party B intend to sign an agreement in the near future. The main contents of the agreement are as follows:
(I) Party B agrees that Party A shall purchase and store the land located at Jiangnan Pharmaceutical Factory, No. 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, with the land use certificate No. 6-3344 of Jinshi Guoyong (2003) Zi. The land is industrial land with a land area of 37016.3 ㎡.
(II) Party A to compensate and reward the above-mentioned land, real estate, equipment and appendages expropriated by Party B, according to the evaluation report issued by Kunyuan Asset Evaluation Co., Ltd. (Kunyuan Evaluation Report [20 14 ] 221 </
More information
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-22
Peak International Trade was rated as "excellent delivery warehouse" by the big business"
On April 12, the 2019 Dalian Commodity Exchange Industrial Products Delivery Work Summary Meeting was held in Dalian. Jianfeng International Trading Company was rated as "2018 (Industrial Products) Excellent Delivery Warehouse" and Ruan Weihang, an employee of the International Trading Company, was rated as "2018 (Industrial Products) Excellent Futures Specialist in Designated Delivery Warehouse". The delivery link is the bridge link between the futures and cash markets, an important area of risk prevention and control in the futures market, and a strong guarantee for the smooth operation and function of the market. Since obtaining the qualification of PVC delivery warehouse in 2009, the chemical warehousing and logistics business of international trading company has developed steadily. In terms of management, the international trading company strictly follows the various systems of the Dalian Commodity Exchange to implement warehouse-in and warehouse-in management. The management level has been improved year by year. Broken packages have been handled on the spot, and the loss of goods has been greatly reduced. The management goal of daily clearing has been achieved, and standardized operations have been achieved; in terms of business marketing, the futures business has driven the gradual development and growth of the spot business, futures varieties have developed from a single PVC variety to four varieties of PVC, PP, PE and plywood. The business volume has increased year by year and has exceeded 500000 tons. The operation volume can exceed 2500 tons/day; In terms of customer service, from zero experience in futures business to now, customer reputation has increased year by year, and customer complaints have gradually decreased. The annual excellent delivery warehouse of the judges is the full affirmation of Dalian Commodity Exchange on the functions of international trading companies, market satisfaction, futures management level and standardization of warehouse daily management. Lou Chunming, general manager of the international trading company, said that the international trading company will implement
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-30
Peak Cement Won the Bid for National Key Project Daye Peak Becomes Huang-Huang Railway Supplier
On March 19, Daye Jianfeng Cement Company officially received a notice from China Railway Construction Material Collection Center that the company was shortlisted for the new Huang (Mei) Huang (Zhou) railway project in the Hubei section of the Shanghai-Chengdu high-speed railway along the Yangtze River in the second place, and obtained the right to supply the 6th package of cement. This is the first stick undertaken by Daye Jianfeng in 2019, and it is also the second time to enter the high-speed rail project after the Wu (Han) Jiu (Jiang) high-speed rail. The Huanghuang high-speed railway is a component of the "eight vertical and eight horizontal" high-speed railway network in the "National Medium and Long-term Railway Network Plan". It is a component of the Wuhan-Hangzhou and Beijing-Hong Kong-Kowloon high-speed railway network. It has a total length of 125 kilometers and a design speed of 350 kilometers per hour. It will start construction at the end of 2018. It will be opened to traffic in 2021. In addition to the characteristics of large demand for high-speed railway and highway projects, the project time span is long and the product quality requirements are high, especially the high-speed railway project has extremely strict requirements on the alkali content of cement. After participating in the bidding, Yuan Xianming, executive deputy general manager of Daye Peak, organized production, quality control, procurement and other relevant departments for many times to carry out tests on the production of low-alkali cement and adjust the proportion of raw materials. The quality control department also sent samples to the provincial professional inspection department for comparative inspection to ensure product stability. The marketing department carefully checked the details of the tender, strictly checked and repeatedly deduced the bid price. Finally, with the full cooperation of all departments, the successful bidding was passed, finalist Huang-Huang high-speed rail project. It is understood that as the country continues to increase investment in infrastructure transportation construction, daye peak adjusted its work direction at the end of 2018, requiring marketing work in 2019 to focus on key projects.
2020
07-31
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-22
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-31